doi:10.3969/j.issn.1673-8640.2021.04.020

Abstract

CLC Number:

R446.1

Figures/Tables 4

References 8

[1]	中华医学会检验医学分会, 国家卫生和计划生育委员会临床检验中心. 便携式血糖仪临床操作和质量管理规范中国专家共识[J]. 中华医学杂志, 2016,96(36):2864-2867.
[2]	杨有业, 张秀明. 临床检验方法学评价[M]. 北京: 人民卫生出版社, 2008.
[3]	HASSLACHER C, KULOZIK F, PLATTEN P. Accuracy of self monitoring blood glucose systems in a clinical setting:application of new planned ISO standards[J]. Clin Lab, 2013,59(7-8):727-733. DOI URL
[4]	章秀兰. 简易血糖仪使用前培训的重要性[J]. 检验医学, 2004,19(4):327-329.
[5]	LODE P V. Point-of-care immunotesting:approaching the analytical performance of central laboratory methods[J]. Clin Biochem, 2005,38(7):591-606. DOI URL
[6]	唐立萍, 居漪, 欧元祝, 等. POCT血糖仪的性能分析[J]. 检验医学, 2010,25(1):13-16.
[7]	GREENBLATT M B, NOWAK J A, QUADE C C, et al. Impact of a prospective review program for reference laboratory testing requests[J]. Am J Clin Pathol, 2015,143(5):627-634. DOI URL PMID
[8]	MANCINI A, ESPOSTO G, MANFRINI S, et al. A real-world setting study:which glucose meter could be the best for POCT use? An easy and applicable protocol during the hospital routine[J]. J Diabetes Sci Technol, 2018,12(5):1053-1060. DOI URL PMID

样本编号	不同检测时间生化分析仪检测结果/（mmol/L）		百分偏移/%	根据检测时间拟定的POCT血糖仪靶值/（mmol/L）
样本编号	10：11	10：40	百分偏移/%	10：11	10：21	10：31	10：40
1	17.08	16.65	2.5	17.08	17.08	16.65	16.65
2	6.39	6.21	2.8	6.39	6.39	6.21	6.21
3	5.15	4.24	17.7	5.15	4.85	4.54	4.24
4	26.92	26.56	1.3	26.74	26.74	26.74	26.74
5	9.98	9.69	2.9	9.98	9.98	9.69	9.69
6	9.29	8.99	3.2	9.29	9.29	8.99	8.99
7	12.65	12.32	2.6	12.65	12.65	12.32	12.32
8	13.22	12.82	3.0	13.22	13.22	12.82	12.82
9	4.18	3.80	9.1	4.18	4.05	3.93	3.80
10	3.21	2.92	9.0	3.21	3.11	3.01	2.92

样本编号	不同检测时间生化分析仪检测结果/（mmol/L）		百分偏移/%	根据检测时间拟定的POCT血糖仪靶值/（mmol/L）
样本编号	10：11	10：40	百分偏移/%	10：11	10：21	10：31	10：40
1	17.08	16.65	2.5	17.08	17.08	16.65	16.65
2	6.39	6.21	2.8	6.39	6.39	6.21	6.21
3	5.15	4.24	17.7	5.15	4.85	4.54	4.24
4	26.92	26.56	1.3	26.74	26.74	26.74	26.74
5	9.98	9.69	2.9	9.98	9.98	9.69	9.69
6	9.29	8.99	3.2	9.29	9.29	8.99	8.99
7	12.65	12.32	2.6	12.65	12.65	12.32	12.32
8	13.22	12.82	3.0	13.22	13.22	12.82	12.82
9	4.18	3.80	9.1	4.18	4.05	3.93	3.80
10	3.21	2.92	9.0	3.21	3.11	3.01	2.92

质评物批号	靶值/ （mmol/L）	允许范围/ （mmol/L）	第1次检测		第2次检测		第3次检测
质评物批号	靶值/ （mmol/L）	允许范围/ （mmol/L）	复测值/（mmol/L）	百分偏移%	复测值/（mmol/L）	百分偏移%	复测值/（mmol/L）	百分偏移%
201911	7.92	7.37~8.47	8.03	1.4	7.98	0.8	8.02	1.3
201912	4.25	3.95~4.55	4.23	-0.5	4.22	-0.7	4.28	0.7
201913	17.97	16.71~19.23	17.86	-0.6	17.66	-1.7	17.66	-1.7
201914	8.74	8.13~9.35	8.79	0.6	8.69	-0.6	8.69	-0.6
201915	12.90	12.00~13.80	12.81	-0.7	12.91	0.1	12.92	0.2

质评物批号	靶值/ （mmol/L）	允许范围/ （mmol/L）	第1次检测		第2次检测		第3次检测
质评物批号	靶值/ （mmol/L）	允许范围/ （mmol/L）	复测值/（mmol/L）	百分偏移%	复测值/（mmol/L）	百分偏移%	复测值/（mmol/L）	百分偏移%
201911	7.92	7.37~8.47	8.03	1.4	7.98	0.8	8.02	1.3
201912	4.25	3.95~4.55	4.23	-0.5	4.22	-0.7	4.28	0.7
201913	17.97	16.71~19.23	17.86	-0.6	17.66	-1.7	17.66	-1.7
201914	8.74	8.13~9.35	8.79	0.6	8.69	-0.6	8.69	-0.6
201915	12.90	12.00~13.80	12.81	-0.7	12.91	0.1	12.92	0.2

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 8

Related Articles 15

Recommended Articles

Metrics